Evolving Role of BTK Inhibitors in CLL: Experts Answer Your Questions

CCO Oncology Podcast

İçerik Clinical Care Options, LLC and Clinical Care Options tarafından sağlanmıştır. Bölümler, grafikler ve podcast açıklamaları dahil tüm podcast içeriği doğrudan Clinical Care Options, LLC and Clinical Care Options veya podcast platform ortağı tarafından yüklenir ve sağlanır. Birinin telif hakkıyla korunan çalışmanızı izniniz olmadan kullandığını düşünüyorsanız burada https://tr.player.fm/legal özetlenen süreci takip edebilirsiniz.

1+ y ago 10:33

MP3•Bölüm sayfası

In this episode, Farrukh T. Awan, MD, and Nicole Lamanna, MD, answer questions from an audience of healthcare professionals on topics related to the use of BTK inhibitors for the management of chronic lymphocytic leukemia (CLL). The topics covered include:

Whether it is justifiable to use chlorambucil plus obinutuzumab as a control arm in a registrational trial today
Relevance of overall response rate vs progression-free survival for BTK inhibitor therapy
Approval of ibrutinib/venetoclax combination therapy for patients with CLL
Key differences between zanubrutinib and acalabrutinib in the treatment of patients with CLL
How to transition/overlap next therapy in patients with CLL with progression while receiving a BTK inhibitor

Faculty:
Farrukh T. Awan, MD
Associate Professor of Internal Medicine
Director of Lymphoid Malignancies Program
Harold C. Simmons Comprehensive Cancer Center
University of Texas Southwestern Medical Center
Dallas, Texas

Nicole Lamanna, MD
Associate Professor
Leukemia Service
Director of CLL Program
Hematologic Malignancies Section
Department of Medicine
New York-Presbyterian/Columbia University Medical Center
New York, New York

Link to the complete program, including downloadable slidesets and an on-demand webcast:
https://bit.ly/3EjvSKm

168 bölüm

#Science #Fitness #Biology #Higher Education #Podcasting Education #Medicine #Clinical Care Options, LLC #Clinical Care Options #Essential Thrombocythemia #Myelofibrosis #Oncology #CME #Nonmalignant Hematological Disorders #Skin Cancer #Hematological Malignancies #Acute Myeloid Leukemia #Kidney Cancer #Melanoma #Gastrointestinal Cancer #Acute Lymphocytic Leukemia #Prostate Cancer #Myeloproliferative Neoplasms #Follicular Lymphoma #Glioblastoma #Nsclc #Multiple Myeloma #Hodgkin Lymphoma #Basal Cell Carcinoma #All #Polycythemia Vera #Breast Cancer #Dlbcl #Head And Neck Cancer #Liver Cancer #Sarcoma #Gastroesophageal Cancer #Lung Cancer #Hepatocellular Carcinoma #Urothelial Carcinoma #Cancer Screening #Renal Cell Carcinoma #AML #Ovarian Cancer #CPE #Lymphoma #Diffuse Large B-cell Lymphoma #Cll #Pancreatic Cancer #Beta-thalassemia #Chronic Myeloid Leukemia